Page 11 - சிறிய செல் நுரையீரல் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin- dependent kinase 4/6, a type of enzyme. For patients with extensive-stage small cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan. Today s approval of Cosela will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy.

Albert deisserothEmily hendersonDivision of nonTherapeutics incDrug administrationSupervisory medical officerNon malignant hematologyDrug evaluationBreakthrough therapyBone marrowLung cancerSmall cell lung cancerஎமிலி ஹென்டர்சன்பிரிவு ஆஃப் அல்லாதசிகிச்சை இன்க்மேற்பார்வை மருத்துவ அதிகாரி